Daptomycin elimination by CVVH in vitro: Evaluation of factors influencing sieving and membrane adsorption

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 3, 2009, Pages 178-186

  Wagner, C C ^a   Steiner, I ^a   Zeitlinger, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hemofiltration; Membrane adsorption; Sieving coefficients

Indexed keywords

DAPTOMYCIN; HUMAN ALBUMIN; RINGER LACTATE SOLUTION; ANTIINFECTIVE AGENT; CEFPIROME; CEPHALOSPORIN DERIVATIVE;

ADSORPTION KINETICS; ARTICLE; CONCENTRATION (PARAMETERS); CONTINUOUS HEMOFILTRATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG PROTEIN BINDING; EXTRACORPOREAL CIRCULATION; HEMOFILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; KIDNEY FUNCTION; MEMBRANE; SIMULATION; ULTRAFILTRATION; ADSORPTION; ARTIFICIAL MEMBRANE; BIOLOGICAL MODEL; BLOOD; DOSE RESPONSE; FLOW KINETICS; HUMAN; METABOLIC CLEARANCE RATE;

ADSORPTION; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOFILTRATION; HUMANS; MEMBRANES, ARTIFICIAL; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; RHEOLOGY;

EID: 65549099732     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47178     Document Type: Article

References (26)

1. Arzuaga A, Isla A, Gascon AR, Maynar J, Corral E, Pedraz JL. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient. Blood Purif. 2006; 24: 347-354.
2. Banyai M, Thalhammer F, El-Menyawi I, Heinz G, Traunmuller F, Siostrzonek P. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. Clin Pharmacol Ther. 2000; 67: 368-372.
3. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif. 2006; 24: 548-554.
4. Colton CK, Henderson LW, Ford CA, Lysaght MJ. Kinetics of hemodiafiltration. I. In vitro transport characteristics of a hollow-fiber blood ultrafilter. J Lab Clin Med. 1975; 85: 355-371.
5. Cubist Pharmaceuticals I. Cubicin SPC (Daptomycin for Injection). Lexington MA 02421 USA; 2007. Cubist Pharmaceuticals Inc.
6. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003; 47: 1318-1323.
7. Frank RD, Farber H, Lanzmich R, Floege J, Kierdorf HP. In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes. Nephrol Dial Transplant. 2002; 17: 1957-1963.
8. Golper TA. Drug removal during continuous hemofiltration or hemodialysis. Contrib Nephrol. 1991; 93: 110-116.
9. Golper TA, Saad AM. Gentamicin and phenytoin sieving through hollow-fiber polysulfone hemofilters. Kidney Int. 1986; 30 937-943.
10. Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs. 2007; 67: 1483-1512.
11. Hansen E, Bucher M, Jakob W, Lemberger P, Kees F. Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. Intens Care Med. 2001; 27: 371-375.
12. Ittner KP, Roth G, Gruber M, Pawlik M, Taeger K. Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro. J Antimicrob Chemother. 2005; 56: 360-364.
13. Jeu L, Fung HB. Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin Ther. 2004; 26: 1728-1757.
14. Jorres A. Acute renal failure. Extracorporeal treatment strategies. Minerva Med. 2002; 93: 329-334.
15. Kraft D, Lode H. Elimination of ampicillin and gentamicin by hemofiltration. Klin Wochenschr. 1979; 57: 195-196.
16. Kroh UF, Dinges GK, Lukasewitz P, Steinhausser WU, Holl TJ, Lennartz H. Elimination of drugs by the new polyamide hemofilter FH77H during various in vitro conditions. Blood Purif. 1998; 16: 49-56.
17. Kronfol NO, Lau AH, Barakat MM. Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration. ASAIO Trans. 1987; 33: 300-303.
18. Lau AH, Kronfol NO. Determinants of drug removal by continuous hemofiltration. Int J Artif Organs. 1994; 17: 373-378.
19. Lee SY, Fan HW, Kuti JL, Nicolau DP. Update on daptomycin: the first approved lipopeptide antibiotic. Exp Opin Pharmacother. 2006; 7: 1381-1397.
20. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy. 2000; 20: 635-643.
21. Meyer TW, Walther JL, Pagtalunan ME, Martinez AW, Torkamani A, Fong PD et al. The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. Kidney Int. 2005; 68: 867-877.
22. Phillips GJ, Davies JG, Olliff CJ, Kingswood C, Street M. Use of in vitro models of haemofiltration and haemodiafiltration to estimate dosage regimens for critically ill patients prescribed cefpirome. J Clin Pharm Ther. 1998; 23: 353-359.
23. Reiter K, Bordoni V, Dall'Olio G, Ricatti MG, Soli M, Ruperti S et al. In vitro removal of therapeutic drugs with a novel adsorbent system. Blood Purif. 2002; 20: 380-388.
24. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intens Care Med. 1995; 21: 612-620.
25. Schroeder TH, Hansen M, Stephan M, Hoffmann E, Unertl K, Krueger WA. Elimination of linezolid by an in vitro extracorporeal circuit model. Int J Artif Organs. 2004; 27: 473-479.
26. Thalhammer F, Schmaldienst S, Elmenyawi I, Atteneder M, Burgmann H, Hollenstein U, Georgopoulos A, Graninger W, Putz D, Rosenkranz AR, Mayer G, Hörl WH, Breyer S. Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes. Clin Pharmacol Ther. 1996; 60: 645-650.